India Montelukast API Market Research Report By Application (Asthma, Allergic Rhinitis, Bronchospasm, Urticaria, Others) - Forecast to 2035

India Montelukast API Market Overview

As per MRFR analysis, the India Montelukast API Market Size was estimated at 56.25 (USD Million) in 2023. The India Montelukast API Market Industry is expected to grow from 63.12 (USD Million) in 2024 to 210 (USD Million) by 2035. The India Montelukast API Market CAGR (growth rate) is expected to be around 11.547% during the forecast period (2025 - 2035).

Key India Montelukast API Market Trends Highlighted

The India Montelukast API market is experiencing substantial trends driven by the increasing prevalence of allergic conditions and asthma among the population. As the prevalence of respiratory disorders continues to rise, there is a growing need for effective treatments. Montelukast is a preferred option due to its safety and efficacy. Critical market drivers are the government's health initiatives to enhance respiratory health, particularly through awareness campaigns.

The market potential for Montelukast APIs has significantly increased as a result of these initiatives, which have emphasized the necessity of accessible and affordable medication in the country. In addition, the trend toward more localized production is generating opportunities for Indian manufacturers, as they can capitalize on the increasing domestic demand and prepare for exports due to favorable regulatory frameworks.

The pharmaceutical sector is encouraged to innovate and improve its production capabilities through the Make in India initiative, which supports its development. This local focus not only reduces dependence on imports but also stimulates the overall economy by creating employment. The pharmaceutical industry has recently been motivated to investigate innovative drug delivery systems.

These systems and products enhance patient adherence in response to the increased interest in biologics and personalized medicine. The Montelukast API market has the potential to benefit from this trend, as companies adjust their products to satisfy the changing needs of patients. Furthermore, the market's scope is further expanded by the emergence of digital health solutions.

These solutions provide a means to improve patient education and streamline prescription processes. In general, these emerging trends and opportunities are fostering the expansion of the India Montelukast API market.

Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review

India Montelukast API Market Drivers

Rising Asthma and Allergic Diseases in India

The increasing prevalence of asthma and allergic diseases in India is a significant driver for the India Montelukast Active Pharmaceutical Ingredient Market Industry. According to the Indian Asthma Care Group, approximately 15% of the Indian population suffers from asthma, with a particularly high incidence in urban areas due to pollution and lifestyle changes.

Organizations such as the Ministry of Health and Family Welfare are actively working to raise awareness and improve treatment options for asthma, which boosts the demand for drugs such as Montelukast. With the rise of asthma-related hospital admissions, estimated to be around 3.6 million annually, the need for effective treatments continues to grow, thereby leading to heightened consumption of the Montelukast API.

Government Initiatives and Increased Healthcare Investment

The Indian government has been reinforcing its healthcare infrastructure, which indirectly benefits the India Montelukast Active Pharmaceutical Ingredient Market Industry. The National Health Policy 2017 aims to increase public health expenditure to 2.5% of GDP by 2025, which translates to enhanced access to healthcare for millions.

This initiative creates an environment that encourages research, development, and demand for pharmaceutical products such as Montelukast. With an estimated increase in healthcare investments of over 10% annually, the growth potential for the Montelukast API market appears promising. The National Pharmaceutical Pricing Authority also plays a vital role in regulating and promoting the fair pricing of essential drugs, further aiding market expansion.

Growing Awareness of Preventive Healthcare

The shift towards preventive healthcare is increasingly prevalent among the Indian population, acting as a catalyst for the India Montelukast Active Pharmaceutical Ingredient Market Industry. A survey conducted by the Indian Market Research Bureau reveals that 65% of Indians now favor preventive medicine and regular health check-ups.

Organizations such as the Indian Medical Association are promoting awareness about the early adoption of long-term treatments for chronic conditions such as asthma. This growing awareness is leading to an increase in the prescription rates for Montelukast, therefore driving the overall market growth. The increase in preventive measures is projected to enhance the consumption of Montelukast by an estimated 20% in the coming years.

Evolving Pharmaceutical Manufacturing Capabilities

The advancement in manufacturing technologies and capabilities in India is positively impacting the India Montelukast Active Pharmaceutical Ingredient Market. As per the Department of Pharmaceuticals, the Indian pharmaceutical industry has seen a shift towards modern manufacturing processes, resulting in enhanced efficiency and reduced costs. The implementation of Good Manufacturing Practices (GMP) is increasing the overall quality of Montelukast production, allowing for more competitive pricing.

This is particularly beneficial for domestic companies to expand their market share. The Hinloopen report indicates that pharmaceutical exports from India are expected to grow substantially, promoting the availability of Montelukast on a global scale and contributing to the domestic market's revenue.

India Montelukast API Market Segment Insights

Montelukast API Market Application Insights

The Application segment of the India Montelukast API Market has gained considerable traction due to the increasing prevalence of respiratory and allergic conditions, particularly in urban populations. With rising pollution levels and lifestyle changes, the demand for effective treatments is becoming more pronounced.

Asthma remains a significant area of focus as it affects millions of individuals across the country, particularly among children, highlighting the need for ongoing Research and Development efforts to enhance treatment options. Furthermore, Allergic Rhinitis is widely recognized as a common ailment, with a considerable portion of the population experiencing symptoms that affect daily life, thus driving market growth.

Bronchospasm represents another critical application as it is often associated with various respiratory diseases, necessitating the need for effective management solutions in healthcare. Additionally, Urticaria, characterized by an allergic reaction leading to hives, contributes to the market's importance as many seek relief from discomfort through pharmacological interventions.

The category of Others encompasses a variety of allergic and respiratory conditions that further underpin the market’s diversity. Each of these applications not only reflects a significant portion of the India Montelukast API Market but also reveals a growing public awareness of health and well-being, indicating a robust growth trajectory.

Factors such as increased healthcare spending, a surge in awareness programs about allergies and asthma, and the ongoing efforts by the government and health organizations to improve healthcare accessibility are expected to continue driving the demand within this segment, presenting opportunities for innovation and market expansions to address unfulfilled needs among patients.

Overall, the Application segment can be seen as a vital contributor to the India Montelukast API Market, aligning well with broader healthcare trends and population health dynamics.

Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review

India Montelukast API Market Key Players and Competitive Insights

The India Montelukast API Market is characterized by a dynamic landscape driven by the increasing demand for asthmatic medications and allergy treatments. As a key player in the pharmaceutical domain, Montelukast serves as a leukotriene receptor antagonist that is widely prescribed for managing asthma and allergic rhinitis.

The market has seen a surge in both domestic and international players due to favorable regulatory policies, along with a growing awareness of respiratory disorders among the Indian population. Competitive insights reveal a blend of established pharma companies and emerging entities working towards innovation and cost-effective production strategies.

This competitive environment is further enhanced by partnerships, collaborations, and advancements in technology, which streamline manufacturing processes and enhance product quality, ensuring a robust supply of high-quality APIs in the market.

Intas Pharmaceuticals stands as a significant contender in the India Montelukast API Market, exemplifying strength through its extensive product portfolio and commitment to research and development. The firm has established its presence through its high-quality production capabilities while maintaining compliance with national and international regulatory standards.

Intas has dedicated substantial resources to R&D, facilitating the introduction of various formulations and generics that cater to the growing needs of patients with respiratory conditions. With robust distribution networks across India, Intas Pharmaceuticals ensures that its Montelukast products are readily available to consumers, thereby strengthening its market influence.

The company's strategic focus on quality and affordable pricing has allowed it to capture a considerable share of the Indian Montelukast segment, highlighting its role as a leader in this competitive landscape.

Jubilant Life Sciences has carved out a noteworthy position within the India Montelukast API Market through its strong focus on manufacturing and supply chain efficiency. Known for its commitment to producing high-quality APIs, the company has integrated advanced technologies into its production processes, ensuring scalability and consistency in its offerings.

Jubilant's portfolio includes a range of products designed to meet various needs in the respiratory therapeutic area, demonstrating its expertise in Montelukast formulations. The company has established a solid market presence due to its strategic partnerships and collaborations, which have bolstered its capabilities and expanded its reach within India.

Furthermore, Jubilant Life Sciences has engaged in mergers and acquisitions that have enhanced its operational strength and boosted its innovation capacity, allowing it to navigate competitive challenges effectively. By continually investing in R&D and maintaining high-quality standards, Jubilant remains a vital player in the Montelukast API segment, contributing to advancements in respiratory healthcare in India.

Key Companies in the India Montelukast API Market Include

• Intas Pharmaceuticals
• Jubilant Life Sciences
• Torrent Pharmaceuticals
• Divis Laboratories
• Glenmark Pharmaceuticals
• Reddy's Laboratories
• Alkem Laboratories
• Zydus Cadila
• Lupin
• Suresh M. Shah & Co.
• Sun Pharmaceuticals
• Aurobindo Pharma
• Cipla
• Mylan
• Wockhardt

India Montelukast API Market Industry Developments

The India Montelukast API Market has witnessed significant developments recently, particularly with the rising demand driven by the increase in respiratory diseases. Companies such as Dr. Reddy's Laboratories and Cipla have reported growth in market valuation due to their successful product launches and improved production capabilities.

In September 2023, Intas Pharmaceuticals expanded its manufacturing facility to enhance its Montelukast API production capacity, contributing to the competitive landscape. Additionally, in August 2023, Jubilant Life Sciences announced an agreement with Zydus Cadila to collaborate on expanding Montelukast API production, indicating a shift towards strategic partnerships.

Major players like Torrent Pharmaceuticals and Glenmark Pharmaceuticals are also focusing on Research and Development to innovate and streamline their Montelukast offerings. Furthermore, mergers and acquisitions have shaped market dynamics, with Aurobindo Pharma acquiring a portfolio of products related to Montelukast API in March 2022, emphasizing the trend of consolidating capabilities among key manufacturers.

Overall, these developments underscore a vibrant and evolving Montelukast API sector in India, characterized by strategic initiatives and robust market growth prospects.

Montelukast API Market Segmentation Insights

Montelukast API Market Application Outlook

• Asthma
• Allergic Rhinitis
• Bronchospasm
• Urticaria
• Others

Report Attribute/Metric Source:	Details
MARKET SIZE 2018	56.25(USD Million)
MARKET SIZE 2024	63.12(USD Million)
MARKET SIZE 2035	210.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	11.547% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Million
KEY COMPANIES PROFILED	Intas Pharmaceuticals, Jubilant Life Sciences, Torrent Pharmaceuticals, Divis Laboratories, Glenmark Pharmaceuticals, Dr. Reddy's Laboratories, Alkem Laboratories, Zydus Cadila, Lupin, Suresh M. Shah & Co., Sun Pharmaceuticals, Aurobindo Pharma, Cipla, Mylan, Wockhardt
SEGMENTS COVERED	Application
KEY MARKET OPPORTUNITIES	Rising asthma prevalence, Expansion of generic drugs, Increasing respiratory disease awareness, Growth in healthcare infrastructure, Favorable regulatory environment
KEY MARKET DYNAMICS	growing asthma prevalence, increasing generic drug adoption, government healthcare initiatives, rising demand for cost-effective medications, strict regulatory compliance
COUNTRIES COVERED	India